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Background: Determining the primary site of metastatic cancer with confidence can be challenging. Pathologists
commonly use a battery of immunohistochemical (IHC) stains to determine the primary site. Gene expression
profiling (GEP) has found increasing use, particularly in the most difficult cases. In this pilot study, a direct
comparison between GEP and IHC-guided methods was performed.
Methods: Ten archived formalin-fixed paraffin embedded metastatic tumor samples for which the primary site had
been clinically determined were selected. Five pathologists who were blinded to the diagnosis were asked to
determine the primary site using IHC and other stains selected from a panel of 84 stains. Each pathologist was
provided patient sex, biopsy site and gross sample description only. Slides were digitized using ScanScopeWXT at
0.25 μm/pixel. Each evaluating pathologist was allowed to provide a diagnosis in three stages: initial (after
reviewing the H&E image), intermediate (after reviewing images from the first batch of stains) and final diagnosis
(after the second batch of stains if requested). GEP was performed using the only FDA-cleared test for this intended
use, the Pathwork Tissue of Origin Test. No sample information was provided for GEP testing except for patient sex.
Results were reported as the tumor tissue type with the highest similarity score.
Results: In this feasibility study, GEP determined the correct primary site in 9 of the 10 cases (90%), compared to
the IHC-guided method which determined the correct primary site for 32 of 50 case evaluations (average 64%,
range 50% to 80%). The five pathologists directing the IHC-guided method ordered an average of 8.8 stains per
case (range 1 to 18). GEP required an average of 3 slides per case (range 1 to 4).
Conclusions: Results of the pilot study suggest that GEP provides correct primary site identification in a higher
percentage of metastatic cases than IHC-guided methods, and uses less tissue. A larger comparative effectiveness
study using this study design is needed to confirm the results.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/1749854104745508
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Determining the primary site of metastatic cancer with
confidence can be challenging; for 3–5% of cancer cases
there is no clinically evident primary site [1-7]. Patholo-
gists commonly use panels of immunohistochemical
(IHC) and histochemical (HC) stains for diagnosis. A ju-
dicious use of lineage and organ-specific tissue markers
is required to diagnose the primary site of metastatic* Correspondence: rpillai@pathworkdx.com
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reproduction in any medium, provided the orcancer, as markers vary in levels of sensitivity and speci-
ficity. [6]
In some cases, however, the primary site cannot be
identified with certainty using conventional IHC evalu-
ation. In a review and meta-analysis of published studies
of IHC accuracy that were adequately blinded, four stud-
ies representing a total of 308 tumor samples reported
average accuracy of 67% on metastatic samples [8].
In recent years, gene expression profiling (GEP) tests and
tests using microRNA markers have been developed to aid
in the diagnosis of difficult-to-diagnose tumors [9-11].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tissue and either microarrays or real-time polymerase chain
reaction technologies to measure levels of multiple markers
followed by application of an algorithm to predict the most
likely primary site for a particular sample.
Recent reports discuss the need to coordinate the use of
available methods of identifying primary site to optimize
patient care [12,13]. However, to date no direct compari-
son of the accuracy of the GEP and IHC-based methods
has been published; more data regarding comparative
effectiveness of the gene expression- and IHC-based
approaches are needed to fully understand the appropriate
use of these two methods.
One of the GEP tests for primary site identification is
the Tissue of Origin Test (Pathwork Diagnostics, RedwoodMedical records searched to fin
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that can confound a comparison – GEP is objective, inde-
pendent of clinical history, based on algorithmic applica-
tions to a dataset, and is a one-time test, whereas
histopathologic evaluation is subjective, reliant on clinical
history and often performed in consultation with other
pathologists [18]. Stains are typically ordered in batches,
and cost considerations may influence how many IHC
stains a pathologist orders. We attempted to eliminate
such confounding sources of variation. We placed no limit
on the number of stains that could be ordered, and
required individual pathologist assessments through a se-
cure web interface that prevented access to evaluations
being conducted by the other participating pathologists.
Both GEP and histopathology were conducted on the
same tissue block and the same restricted information of
patient gender and minimal gross description of the speci-
men was made available for both methods.
This publication describes the novel methods used to
conduct the study, results of the pilot project, and pro-
vides information needed for conducting a more com-
prehensive study.
Methods
Archived human formalin-fixed paraffin-embedded
(FFPE) specimens (blocks) containing metastatic tumors
with a clinically established primary site were used. Sam-
ples were coded and both the evaluating pathologists
and the laboratory performing the GEP at Pathwork
Diagnostics were blinded to the primary site. The study
was conducted under an Institutional Review Board-
approved protocol. The overall study design and work-
flow is illustrated in Figure 1. Medical records from
2007 to 2011 were reviewed from two hospitals (The Re-
gional Medical Center at Memphis, and Methodist Uni-
versity Hospital, Memphis, TN) to select cases with
biopsy proven metastatic cancer chosen by the Principal
Investigator to resemble cases on which GEP may be
used in clinical practice, i.e. where the diagnosis was not
always obvious upon morphology review.
Specimen inclusion criteria
The selection criteria were as follows. (i) The sample
represented a FFPE metastatic tumor with a known pri-
mary site as determined by review of the medical
records. The determination of primary site was based on
all available clinical information, but was not accepted
when the diagnosis was made exclusively using immuno-
histochemistry (IHC) or special stains. (ii) All tumor
samples were selected from a panel of 15 tumor tissue
types covered by the Tissue of Origin Test. These types
include: bladder (BL), breast (BR), colorectal (CO), gas-
tric (GA), testicular germ cell (GC), kidney (KI), hepato-
cellular (LI), non-small cell lung (LU), non-Hodgkin’slymphoma (LY), melanoma (ME), ovarian (OV), pan-
creas (PA), prostate (PR), thyroid (TH) and sarcoma
(SC). (iii) The FFPE tissues submitted on unstained
slides or paraffin blocks were checked for adequacy of
tissue required for the study. Samples had to be suffi-
cient to produce at least 25 5-μm-thick (+/− 1 μm) sec-
tions: (a) the first and last sections for staining with
hematoxylin and eosin (H&E) stain, (b) eight unstained
slides (USS) containing no less than 1 mm2 of tumor tis-
sue for GEP, and (c) at least 15 unstained slides for IHC
staining and analysis. (iv) H&E stained slides were evalu-
ated by a board certified pathologist to verify tumor con-
tent. All specimens were estimated to contain ≥ 60%
non-necrotic tumor tissue (tumor and stroma) in the
first and last H&E stained slide and (v) found to be con-
sistent with the reported histology on quality review by a
board-certified pathologist. If the number of stains
ordered exceeded the number of slides that were cut ini-
tially, additional slides were prepared from the block,
and the last slide was stained with H&E to verify that at
least 60% tumor content remained.Staining procedure and quality control
All stains were performed in a CLIA-certified laboratory
by a histotechnologist with more than 20 years of IHC
staining experience. All IHC stains were performed on a
Ventana Benchmark W LT automated immunohisto-
chemical stainer. Relevant controls were included with
each batch of stains. Prior to study initiation, a panel of
84 stains was agreed upon by all investigators, and made
available for the study. This included 73 IHC stains and
11 histochemical stains (Table 1). Evaluating pathologists
were free to order as many stains as desired from the list
of stains in two rounds of requests.Digitizing stained slides
All H&E slides and IHC stained slides were digitized using
a Whole Slide Imaging (WSI) system (ScanScopeWXT,
AperioW Technologies, Inc., San Diego, CA). All slides
were scanned at 0.25 μm/pixel resolution, and the images
saved in the password-protected database (Spectrum ver-
sion 10.2.2.2314) provided by AperioW on a web-accessible
server. All digitized images were reviewed by a board-
certified pathologist for quality assurance.Selection of evaluating pathologists
Five board-certified pathologists with a wide range of ex-
perience (3 to 30+ years post pathology training) and
from a diverse set of institutions (academic centers,
community practice, and pathology reference laboratory)
were selected for evaluating the cases. All evaluating
pathologists confirmed previous use of digital pathology.
Table 1 Pre-established list of immunohistochemical (IHC) and histochemical (HC) stains made available to evaluating
pathologists
No. IHC Stain No. IHC Stain No. IHC Stain No. HC Stain
1 Actin, muscle specific 26 CK17 51 Myogenin 1 Alcian blue- PAS
2 AE1/AE3 27 CK19 52 Napsin A 2 Argentaffin
3 AFP 28 CK5/6 53 NSE 3 Argyrophil
4 hCG 29 Pancytokeratin 54 OCT-4 4 Colloidal iron stain
5 CA-125 30 Desmin 55 P504S 5 Elastic, Verhoeff’s
6 Calcitonin 31 E-cadherin 56 p53 6 Mucicarmine
7 Caldesmon 32 EMA 57 p63 7 PAS
8 Calretinin 33 Estrogen Receptor 58 PAX-2 8 PASD
9 CAM 5.2 34 GCDFP-15 59 PAX5 9 PTAH
10 CD10 35 GFAP 60 PAX-8 10 Reticulum, Gomori’s
11 CD117 36 Glypican-3 61 PLAP 11 Trichrome, Masson’s
12 CD138 37 Hep-Par1 62 Progesterone Receptor
13 CD20 38 HMB 45 63 Prostate Specific Antigen
14 CD3 39 HMW Keratin 64 RCC
15 CD30 40 HNF-1 65 S-100
16 CD34 41 Inhibin 66 Synaptophysin
17 CD43 42 CK, Oscar 67 Thrombomodulin
18 CD45RO 43 Leucocyte Common Antigen 68 Thyroglobulin
19 CD56 44 Mammaglobin 69 TTF1
20 CD99 45 Melan-A 70 Uroplakin
21 CDX2 46 MOC-31 71 Villin
22 CEA-polyclonal 47 MUC 1 72 Vimentin
23 Chromogranin 48 MUC 2 73 WT-1
24 CK 20 49 MUC5AC
25 CK 7 50 Myeloperoxidase
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A web-accessible user interface was designed (OneTera
LLC, San Francisco, CA) for evaluating pathologists to ac-
cess the images in the Spectrum database, order stains as
needed, and record diagnoses and associated confidence
levels. This information was collected at the following
points: a) after review of the H&E slide alone b) after re-
view of the first batch of stains, and c) after review of the
second batch of stains. Each evaluating pathologist (EP)
had secure password-protected access to the interface. All
10 cases were evaluated by each EP. One H&E image was
provided to all EPs as the starting point for each case.
Each pathologist had access only to IHC stains that they
had ordered; if a stain was ordered by more than one
pathologist, requestors were provided with a copy of the
same digital image. This added control and reduced vari-
ability in interpretation that might be attributed to the
staining procedure or tumor heterogeneity.
Prediction of primary site using IHC and special stains
The EPs were blinded to the clinical history and tissue of
origin for the samples. They received only the patient’s sexand gross sample description for each case, including bi-
opsy site, given in Table 2. Each EP first reviewed the H&E
image, recorded an Initial diagnosis (Stage 1) with a level
of confidence, and ordered the first round of stains from
the panel in Table 1. The digitized images for these stains
were provided after two working days. The EP reviewed
the stain images, recorded an Intermediate diagnosis
(Stage 2) with a level of confidence, and ordered the sec-
ond and final round of stains from the panel in Table 1.
As before, the digitized images for these stains were pro-
vided after two working days. The EP reviewed the stain
images and recorded the Final diagnosis (Stage 3) with a
level of confidence. The EP had the opportunity to provide
a final diagnosis at any of the three stages: after the first
review of the H&E image, after the first round of stains, or
after the second round of stains. If the EP chose to deliver
a final diagnosis at Stage 1 or Stage 2, the EP was
prompted by the software to verify that this was
intentional. Once the final diagnosis was provided, the EP
received a system-generated e-mail with a link to the case.
The EP had the option to alter the final diagnosis within
24 hours of receiving this email. After 24 hours, the case








1 Female Ovary Omentum This specimen received labeled with patient’s name are two, pink-yellow, lobulated omental tissue
fragments measuring 14.5 × 7.0 × 1.0 cm in aggregate. Sectioning omentum reveals yellow lobulated
adipose tissue marked by multiple, firm, yellow-white nodule varying in size from 0.5 × 0.5 × 0.5 cm. up to
2.0 × 1.5 × 1.0 cm. Some of these nodules show focal hemorrhage and necrosis. Representative sections are
submitted in cassette. Two pieces.
2 Male Colorectal Liver The specimen consists of a 360 gram, 16.5 × 7.0 × 7.0 cm segment of liver. The superior portion of the liver
has been inked yellow, and the resection margin has been inked black. The liver has a pink-tan
appearance with adhesions. Previous sectioning revealed a 2.5 × 2.5 cm white-tan nodule located
approximately 6.0 cm from the superior portion of the liver and comes to within 1.0 cm from the
resection margin. Located approximately 1.5 cm inferior to the first nodule are 2 additional white-tan,
circumscribed nodules. These measure 0.2 cm and 1.3 cm in greatest dimension. The larger nodule comes
to within 0.5 cm from the resection margin, and the smaller nodule comes to within 2.2 cm from the
resection margin. The remaining liver has a green-brown appearance, and no additional areas of interest
are identified. Second and third nodules are submitted in one cassette, 1 piece.
3 Male Colorectal Brain Specimen received labeled with right frontal brain tumor. Received is a 3.0 × 2.1 × 0.3 cm aggregate of
gray-tan, friable tissue fragments. Tea bag. 1 cassette, all.
4 Female Breast Lymph
Node
This specimen received labeled with patient’s name. Contains 1 possible lymph node, 1 piece.
5 Male Kidney Brain The specimen consists of a previously sectioned portion of red-gray brain tissue which upon
reconstruction measures 4.0 × 3.1 × 2.0 cm. There is a 3.5 × 2.0 × 1.1 cm ill-defined yellow-gray mass which
comes to within 0.3 cm of the margin. The margin has been inked black. The remaining cut surface is
gray-pink, and no additional masses or areas of interest are grossly identified. Representative tissue is
submitted in 1 cassette, 1 piece.
6 Female Melanoma Lymph
Node
Possible lymph nodes, 1 cassette, multiple pieces.
7 Male Bladder Lymph
Node
The specimen received consists of multiple fragments of fat and soft connective tissue. On sectioning, the
fragments consist of possible lymph nodes ranging from 0.7 cm up to 4.3 cm in greatest dimension. The
cut surfaces are solid gray-white. Possible lymph nodes, multiple pieces.
8 Male Sarcoma Liver Received is a 1765 gram, 20.7 × 14.3 × 10.8 cm right lobe of liver. There is a stitch attached to the anterior
aspect of the capsule. The resection margin will be inked black. On sectioning, there is a 10.4 × 6.8 cm
white-tan, fleshy, friable mass. The mass is focally necrotic and in the area where the mass is necrotic, it is
cystic. The mass grossly appears to come to within 1.1 cm of the resection margin. The remaining liver is
red-brown and no satellite lesions or other masses are grossly identified. 1 cassette, 1 piece.
9 Male Gastric Omentum The specimen consists of a 0.9 × 0.7 × 0.5 cm portion of yellow, lobulated omentum with a 1.2 cm firm,
gray nodule. 1 cassette, 1 piece.
10 Male Lung Brain The specimen consists of a 1.6 × 1.3 × 0.7 cm aggregate of soft tan-brown tissue fragments. Submitted in 1
cassette, multiple pieces.
* - Information given to EPs.
** - Information given for GEP testing to Pathwork Diagnostics Laboratory.
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could be made. When two or more EP ordered the same
stain, the same stain image was provided to the second
ordering EP with the standard two working day delay, to
ensure that no participant would be able to infer that the
stain had been requested by another. The rationale for this
was to ensure that the digital pathology and web interface
did not provide indirect "cross talk" between EPs, i.e. to
eliminate inadvertent clues on stains that were ordered by
others which might allow an individual EP to infer the dir-
ection another EPs investigation was following.
Gene expression profiling test methodology
The specimens were processed for the PathworkW Tissue
of Origin Test at Pathwork Diagnostics Laboratory
(PWDL) as described previously [14]. Unstained slides
contained an identifiable tumor region that was at least1 mm2 in area. To increase the percent tumor in the
submitted sample, tumor tissue was microdissected
(scraped) from the slides and placed into vials for RNA
extraction. Total RNA was isolated using the Agen-
courtW FormaPure Kit (Beckman–Coulter Genomics,
Beverly, MA). The total RNA was processed to prepare
labeled cDNA for hybridization to PathchipW microar-
rays manufactured by Affymetrix (Santa Clara, CA) with
a two-cycle amplification method using the RampUP Kit
(Genisphere, Hatfield, PA). A positive/negative total
RNA control was run with every amplification batch.
The microarrays were washed and stained using the
GeneChipW Hybridization Wash and Stain kit in a Gene-
Chip Fluidics Station FS450Dx, and scanned with a Gen-
eChip Scanner 3000Dx (Affymetrix). Microarray data
files (CEL) that passed data verification [14] were ana-
lyzed using the Tissue of Origin Test algorithm, a 2000-
Kulkarni et al. Diagnostic Pathology 2012, 7:110 Page 6 of 10
http://www.diagnosticpathology.org/content/7/1/110gene classification model which quantifies the similarity
between RNA expression patterns of a study specimen
and the 15 tissues on the test panel. Data were reported
as Similarity Scores (SS) for each tissue, measures of the
similarity of the RNA expression pattern of the specimen
to the RNA expression pattern of the indicated tissue.
Similarity Scores ranged from 0 (very low similarity) to
100 (very high similarity) and summed to 100 across all
15 tissues on the panel. The highest SS indicated the
likely tissue of origin, with two exceptions: (i) If the
highest score was less than 20, no tumor tissue type was
predicted, and (ii) If the patient was male, and the high-
est SS was for ovarian cancer, and the second highest SS
was for testicular germ cell cancer, the result was tes-
ticular germ cell cancer. For any tissue type with SS of
≤ 5, the possibility of that particular tissue type as the
likely tissue of origin was ruled out. The Tissue of Origin
Test result was automatically generated by the computer
algorithm using only gene expression values as input.
No clinical history, reference diagnosis or biopsy site in-
formation was used.
It should be noted that in clinical practice, a PWDL
pathologist provides an interpretation of the test results
along with a confidence level. This is based on test per-
formance information derived from analyses of results
from the clinical validation study [14], as well as histo-
pathologic appearance, and relevant clinical information.
In this study, the primary analysis was conducted using
the highest SS. A PWDL pathologist recorded an inter-
pretation of the results while blinded to the primary site,
and this information was available for secondary analyses.
Results
Ten metastatic specimens were selected from among
common solid malignancies representing nine different
primary sites, and four metastatic sites, as shown inTable 3 Number of stains ordered per case, per round























Case 1 8 6 13 9 6 3 0 0 4 0 4
Case 2 3 4 9 6 4 0 0 0 1 0 2
Case 3 3 4 7 7 4 0 0 0 0 0 2
Case 4 9 6 12 7 7 7 3 4 6 0 6
Case 5 3 6 9 9 5 0 0 0 4 0 3
Case 6 7 6 13 9 8 9 2 5 2 0 6
Case 7 7 6 11 7 6 8 4 0 3 0 5
Case 8 10 5 11 8 5 0 2 0 7 0 4
Case 9 6 7 11 10 6 0 2 0 8 2 5
Case 10 4 5 10 8 1 0 3 0 0 0 3Table 2. All specimens had at least 60% non-necrotic
tumor content.
Five pathologists reviewed 10 cases each, for a total of
50 case reviews. The average number of stains ordered by
an EP in the first round was 7.06. For 21 of 50 (42%) of
the case reviews the EPs ordered a second round of stains
with an average of 4.2 stains for each of these cases. From
among the 442 total stains ordered by all the EPs for all
the cases, an average of 22 unique stains per case was
ordered by the group of five EPs. None of the EPs ordered
histochemical stains other than IHC stains. The number
of stains ordered for each case by individual EPs is shown
in Table 3 and the twenty most commonly ordered stains
are shown in Table 4. In decreasing order of frequency,
the most commonly ordered stains were CK 7, CK 20,
TTF-1, CDX-2, PAX-8, estrogen receptor, napsin A, PAX-
2, p63, and synaptophysin. The average number of stains
ordered by an evaluating pathologist (EP) per case was 8.8
(median 8, range 1 to 18).
The diagnoses of primary site reached by each EP and
the predictions of primary site by the GEP test are shown
in Table 5. Following review of H&E slides alone, EPs
reached the correct diagnosis of primary site for 21 of 50
case reviews (42% accuracy). Following review of the first
round of IHC stains, the EPs reached the correct diagnosis
of primary site in 31 of 50 case reviews (62% accuracy).
Following the review of all IHC stains (either one round
for 29 cases or two rounds of IHC for 21 cases), the EPs
reached the correct diagnosis of primary site in 32 of 50
case reviews (64% accuracy). Accuracy among EPs ranged
from 50% to 80%. For each EP, the accuracy increased
considerably between the H&E and first round, but not
between the first and second round (Table 5). In 29 out of
50 case reviews, EPs provided a final diagnosis after order-
ing only the first batch of stains. The average accuracy for










9 22 6-13 9.8 2
7 10 3-9 5.4 4
5 7 3-7 5.0 2
1 28 7-16 12.2 2
6 20 3-13 7.2 2
1 31 8-18 12.2 6
2 25 6-15 9.8 2
8 28 5-15 9.6 2
2 30 6-18 10.4 4
1 15 1-10 6.2 4
Table 4 The numbers of EPs ordering each stain is shown by stain and case for the 20 stains most commonly ordered
Reference diagnosis Ovary Colorectal Colorectal Breast Kidney Melanoma Bladder Sarcoma Gastric Lung Total
stains
ordered
Case Number Case 1 Case 2 Case 3 Case 4 Case 5 Case 6 Case 7 Case 8 Case 9 Case 10
Stain Name
CK 7 5 5 5 4 2 4 5 2 4 4 40
CK 20 5 5 5 4 2 3 5 2 3 4 38
TTF1 3 3 4 5 3 4 5 2 3 3 35
CDX-2 2 5 5 4 1 2 5 1 4 1 30
PAX-8 3 2 4 5 3 2 2 1 2 24
Estrogen receptor 5 4 1 4 1 1 16
Napsin A 1 2 2 3 1 2 1 1 1 14
PAX-2 1 1 2 3 2 2 1 1 1 14
p63 3 1 4 2 4 14
Synaptophysin 2 1 1 2 1 1 2 2 1 13
Mammaglobin 3 3 3 1 2 12
GCDFP-15 3 4 2 2 1 12
Villin 1 2 2 1 1 1 1 2 1 12
S-100 1 4 4 1 10
WT-1 4 3 1 1 9
Pancytokeratin 1 1 2 1 2 1 1 9
PSA 1 2 1 3 2 9
CK 5/6 2 1 2 2 2 9
Hep-par 1 3 3 1 8
HMB 45 1 4 3 8
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curacy was 62%.
The variation in the total number of stains requested
by all 5 EPs per case may be indicative of relative diag-
nostic complexity. Using this measure, case 3 was the
simplest, and all EPs provided a final diagnosis without
ordering a second round of stains. One EP diagnosed
the case with as few as 3 stains. The average number of
stains used by all EPs was 5 (median 4, range 3–7). Case
6 was the most complex: no EP required fewer than 8
stains, and the average across all EPs was 12.2 (median
11, range 8 to 18). For both cases, all EPs and the GEP
test correctly determined the primary site.
The GEP test determined the correct diagnosis in 90%
(9/10) of cases. The range of highest SS was 24.4 to 97.6
(Table 5). The average number of slides used for the
GEP test was three (median 2, range 2 to 6; Table 3). For
cases 3 and 6, the numbers of slides used for the GEP
test were 2 and 6, respectively.
Discussion
We have devised and tested a novel approach for dir-
ectly comparing a GEP test to special stain evaluation
using multiple evaluating pathologists. The study design
reduced subjectivity of the pathologic diagnosis and
minimized the variables between the two approachesbeing compared. The use of a single central laboratory
to perform IHC staining and digital pathology to provide
the results to multiple participating pathologists elimi-
nated the need for shipping slides from one site to an-
other for pathologist evaluation, thus enabling more
efficient study logistics and timelines. The whole slide
imaging system created a digital replica of the entire
content of a glass microscope slide on the computer,
closely emulating traditional viewing of a slide with a
conventional microscope [19]. EPs could zoom in or pan
out of the web-accessible, interactive images for evalu-
ation. The system also allowed proper control, providing
access to only the stains requested by each pathologist,
maintaining sample blinding and preventing indirect
“cross-talk” between EPs. All the EPs were given access
to images after 48 hours of ordering stains, eliminating
the possibility of indirect clues to EPs regarding stains
ordered by other EPs. All the slides were stained in one
CLIA certified laboratory by an experienced histotech-
nologist using the same IHC staining instrument, thus
avoiding technical variability. All the slides were digi-
tized using only one scanner and the images were
checked for quality assurance by an experienced board
certified pathologist, creating uniformity in the image
quality. All the images were web-accessible using a
password-protected database, allowing uniformity in
Table 5 Diagnoses provided by evaluating pathologists and GEP test vs. the reference diagnosis
Case No. Reference
Diagnosis




H&E Int Final All H&E Int Final All H&E Int Final All H&E Int Final All H&E Int Final All H&E Int All
Case 1 OV F OV 97.6 BR OV OV OV OV OV OV OV OV OV OV OV OV OV OV OV OV – – –
Case 2 CO M CO 89.9 CO CO CO CO CO CO CO CO CO PA PA PA CO LU LU LU – – –
Case 3 CO M CO 87.6 CO CO CO CO CO CO CO CO CO LU CO CO CO CO CO CO – – –
Case 4 BR F BR 97.6 LU OV OV OV LU LU LU BR BR PA PA OV OV PA PA OV OV OV OV – – –
Case 5 KI M KI 86.4 KI KI KI KI KI KI KI KI KI LU KI KI KI KI KI KI – – –
Case 6 ME F ME 67.4 LY ME ME ME BR BR BR LI ME ME ME BR ME ME ME LU ME ME ME – – –
Case 7 BL M BL 45.1 GC PA BL LU GA GA LU LU BL BL LU BL BL BR BL PA PA – – –
Case 8 SC M SC 76.1 SC SC SC LI SC SC SC SC SC SC LI ME ME KI LI LI LI – – –
Case 9 GA M GA 36.9 GA GA GA SC GA GA GA GA GA GA GA PA PA PA LY GA GA GA – – –
Case 10 LU M OV 24.4 BL BL BL BL BL BL BL BL BL BL BL BL BL BL BL BL BL – – –
No.
incorrect
1 5 3 2 6 4 4 3 2 2 9 5 5 6 4 5 5 29 19 18
No.
correct
9 5 7 8 4 6 6 7 8 8 1 5 5 4 6 5 5 21 31 32
% correct 90% 50% 70% 80% 40% 60% 60% 70% 80% 80% 10% 50% 50% 40% 60% 50% 50% 42% 62% 64%
The tumor tissue is indicated by a two-letter code: bladder (BL), breast (BR), colorectal (CO), gastric (GA), testicular germ cell (GC), kidney (KI), hepatocellular (LI), non-small cell lung (LU), non-Hodgkin’s lymphoma (LY),
melanoma (ME), ovarian (OV), pancreas (PA), prostate (PR), thyroid (TH) and sarcoma (SC). SS – Similarity Score, a measure of the similarity of the RNA expression pattern of the specimen to the RNA expression pattern
of the indicated tissue. Similarity Scores range from 0 (very low similarity) to 100 (very high similarity) and sum to 100 across all 15 tissues on the GEP Test panel. The incorrect predictions are indicated with yellow
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http://www.diagnosticpathology.org/content/7/1/110evaluation to all the EPs. In this study, there was no re-
striction on the number of stains that could be ordered.
The studies in the meta-analysis [8] restricted the num-
ber of markers or IHCs in a panel to between 4 to 10,
and the number of tissues of origin represented were
limited to 5 to 7. In clinical practice, GEP is used as an
aid to diagnosis that the pathologist uses along with all
the other histopathologic and clinical information to ar-
rive at a diagnosis. The stringent study design that we
created allowed direct comparison between GEP and
histopathologic evaluation.
All 5 EPs and the GEP test provided a final diagnosis on
all 10 cases. Case 3 was of very low morphological difficulty
and all EPs provided a final diagnosis that matched the
reference diagnosis while ordering the smallest number of
stains (total stains 25 among five EPs). Cases 4 and 10 were
incorrectly diagnosed by all 5 EPs and warrant further dis-
cussion. The patient information provided to all the EPs
and the GEP testing laboratory is shown in Table 2. For
case 4, the primary site was correctly predicted by the GEP
test but missed by all 5 EPs. EPs ordered a total of 61 stains;
the most common being TTF1, CK7, CK20, CDX-2, PAX-
2, ER and GCDFP-15. Case 4 has a somewhat confounding
immunophenotype and an inconclusive appearance on
H&E evaluation. In the GEP test clinical validation study
[14], it was shown that there is a strong positive relation-
ship between the Similarity Score and the probability that
the TOO test prediction is correct. The highest SS gener-
ated by the GEP test was 97.6 (out of a possible 100), indi-
cating a very high confidence in the prediction. For Case
10, neither the diagnoses reached by the EPs nor the TOO
prediction matched the reference diagnosis of lung (squa-
mous cell carcinoma). All EPs delivered a final diagnosis of
bladder. Relevant IHC results for this case include positive
CK7 and negative CK20, TTF-1, and uroplakin. These IHC
results are fully consistent with the reference diagnosis. It is
possible that the H&E appearance of this neoplasm (lack of
keratinization and ribbon-like growth pattern) encouraged
the EPs diagnosis of urothelial carcinoma. For Case 10, the
highest SS generated was 24.4, indicating a relatively low
confidence of prediction. Neither breast cancer (SS 22.9)
nor non-small cell lung cancer (SS 20.8) have been
excluded by the TOO test results, and would be considered
possible primary sites. Bladder cancer has a very low score
of 5.2, and while not formally ruled out (i.e. SS < 5), would
be considered highly unlikely as a primary site.
The PWDL pathologist interpreting the GEP results
favored a non-small cell lung origin, since a prediction
of ovarian was implausible in males and the pattern of
scores was most consistent with a non-small cell lung
origin. The full value of GEP and other novel molecular
evaluations in oncology will most likely be achieved by a
judicious incorporation into the final pathologist con-
sultation report [13].The amount of tissue used by each testing method is an
important consideration in evaluating tissue-based diagnos-
tics. GEP used an average of three slides per case, whereas
the EPs used an average of nine slides per EP per case. In
this sample set, molecular testing required less tissue and
reduced the risk of tissue depletion. For some cases (1, 4, 6,
7, 8 and 9) EPs ordered a large number of stains (average
11 slides per EP per case); whereas in cases 2, 3, 5 and 10
they ordered fewer IHC stains (average 6 slides per EP per
case). The GEP test used 3 slides on average for both sets.
In this pilot study GEP performed favorably (90% accur-
acy) compared to histopathologic evaluation (average 64%
accuracy) by 5 EPs. It is interesting to note that the average
accuracy seen in this study is very similar to the average
67% accuracy reported in the previous meta-analysis [8]. In
this study, there was no restriction on the number of IHCs,
whereas the studies in the meta-analysis restricted the
number of stains to between 4 and 10. While the sample
numbers are small and do not support statistical analyses,
this pilot study has established feasibility for a study with
larger sample size that will be adequately powered to derive
statistically significant conclusions regarding the compara-
tive effectiveness of the two approaches.
Conclusions
This pilot study of 10 samples found important differences
in accuracy between two methods. In the 10 metastatic
samples reported here, GEP identified the correct primary
site more often than the IHC-guided methods used by the
pathologists participating in the study. This study design
will be applied to a larger set of samples to provide a sta-
tistically powered assessment of the comparative effective-
ness of the GEP and IHC-guided methods.
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